Aims/hypothesis Loss of functional beta cells results in a gradual progression of insulin insufficiency in Wolfram syndrome caused by recessive WFS1 mutations. However, beta cell dysfunction in Wolfram syndrome has yet to be fully characterised, and there are also no specific treatment recommendations. In this study, we aimed to characterise beta cell secretory defects and to examine the potential effects of a glucagon-like peptide-1 (GLP-1) receptor agonist on diabetes in Wolfram syndrome. Methods Insulin secretory function was assessed by the pancreatic perfusion method in mice used as a model of Wolfram syndrome. In addition, granule dynamics in living beta cells were examined using total internal reflection fluorescence microscopy. Acute and chronic effects of exendin-4 (Ex-4) on glucose tolerance and insulin secretion were examined in young Wfs1 −/− mice without hyperglycaemia. Molecular events associated with Ex-4 treatment were investigated using pancreatic sections and isolated islets. In addition, we retrospectively observed a woman with Wolfram syndrome who had been treated with liraglutide for 24 weeks. Results Treatment with liraglutide ameliorated our patient's glycaemic control and resulted in a 20% reduction of daily insulin dose along with an off-drug elevation of fasting C-peptide immunoreactivity. Glucose-stimulated first-phase insulin secretion and potassium-stimulated insulin secretion decreased by 53% and 59%, respectively, in perfused pancreases of 10-week-old Wfs1 −/− mice compared with wild-type (WT) mice. The number of insulin granule fusion events in the first phase decreased by 41% in Wfs1 −/− beta cells compared with WT beta cells. Perfusion with Ex-4 increased insulin release in the first and second phases by 3.9-fold and 5.6-fold, respectively, in Wfs1 −/− mice compared with perfusion with saline as a control. The physiological relevance of the effects of Ex-4 was shown by the fact that a single administration potentiated glucose-stimulated insulin secretion and improved glucose tolerance in Wfs1 −/− mice. Four weeks of administration of Ex-4 resulted in an off-drug amelioration of glucose excursions after glucose loading in Wfs1 −/− mice, with insulin secretory dynamics that were indistinguishable from those in WT mice, despite the fact that there was no alteration in beta cell mass. In association with the functional improvements, Ex-4 treatment reversed the increases in phosphorylated eukaryotic initiation factor (EIF2α) and thioredoxin interacting protein (TXNIP), and the decrease in phosphorylated AMP-activated kinase (AMPK), in the beta cells of the Wfs1 −/− mice.
Introduction
Wolfram syndrome (OMIM 222300) is an autosomal recessive disorder characterised by a combination of juvenile-onset diabetes mellitus, optic atrophy, diabetes insipidus, deafness and neurodegeneration [1, 2] . Diabetes mellitus, the earliest manifestation, is followed by the onset of the other clinical features [1, 3, 4] . Autopsy analysis has revealed a selective loss of pancreatic beta cells in affected individuals, accounting for the insulin insufficiency [5] . Since genetic analysis has identified the major causative gene (WFS1) [6] [7] [8] , the combination of known phenotypes and insights into the molecular genetics of WFS1 has allowed a better understanding of this complicated disease.
WFS1 encodes a 100 kDa protein (Wolfram syndrome 1 [WFS1]), which is localised in the endoplasmic reticulum (ER) [9] as well as in secretory granules in mouse pancreatic beta cells [10] . The disruption of this gene in mice (Wfs1 −/− ) predisposes beta cells to ER stress through perturbations of cellular Ca 2+ homeostasis [11] [12] [13] and aberrant ER stress responses [14] , accounting for the beta cell dysfunction and cellular loss seen. In addition, previous studies have demonstrated that WFS1 is required for maintaining the acidic environment of the insulin granules [10] , suggesting that WFS1 contributes to insulin biosynthesis and vesicle exocytosis by producing a suitable pH of the insulin granules to maintain such cellular processes [15, 16] . Although the secretory defects in Wfs1 −/− mice have yet to be fully characterised, they interact with the processes of beta cell failure.
As beta cells are the most susceptible tissues in Wolfram syndrome, diabetes mellitus in humans develops during childhood and is an important target for intervention. Although molecular and cellular experiments have focused on the underlying pathophysiology [14, 17, 18] , research into interventions targeting the processes of beta cell failure and their clinical correlates is still in its infancy. Our present goal was to elucidate the therapeutic effects on insulin insufficiency in Wolfram syndrome of activating the glucagon-like peptide-1 (GLP-1) receptor signal. We also retrospectively observed the effects of liraglutide treatment on beta cell function and glycaemic control in an insulin-dependent woman with Wolfram syndrome. We further studied the alterations of insulin secretion at the systemic and cellular levels in Wfs1 
Methods
Clinical data collection A 25-year-old Japanese woman was diagnosed with Wolfram syndrome based on findings of insulin-dependent diabetes mellitus, optic atrophy, hearing loss and diabetes insipidus. Her diabetes mellitus had been diagnosed at the age of 5 years, and this was followed by optic atrophy and other manifestations (see electronic supplementary material [ESM) Table 1 ). She had become blind at the age of 20. Her parents were consanguineous, and she had two siblings who had been diagnosed with Wolfram syndrome. She had been reported to harbour a homozygous 1515_1530del, p.508Y_L512 mutation in exon 8 of the WFS1 gene (ESM Table 1 ) [8] . She had started insulin therapy at the age of 15, and experienced fluctuations of blood glucose with recurrent episodes of hypoglycaemia. However, no diabetic microvascular complications had so far developed. She was being treated with subcutaneous injections of liraglutide at a dose of 0.9 mg once daily, which is the dosage approved in Japan, in combination with insulin therapy. Before this intervention, she had been admitted to hospital and her residual beta cell function assessed.
We retrospectively studied this participant's clinical course of intervention with liraglutide. All clinical data were collected at the Akita University hospital. The difference (Δ) in Cpeptide immunoreactivity (CPR) was assessed using the following formula: (CPR at 6 min after intravenous infusion of 1 mg of glucagon) − (basal CPR). The secretory units of islets in transplantation (SUIT) index and CPR index (CPI) were calculated as previously described [19] . The collection and use of retrospective clinical data were approved by the institutional review board of the Akita University hospital (approval number 723) and Yamaguchi University hospital (approval number H22-47-2), and appropriate written informed consent was obtained from the patient.
Animal studies The Wfs1 knockout (Wfs1 −/− ) mice, with a C57BL/6J background, were obtained as described [12] and were housed with a free access to food and water in pathogenfree facilities with a 12 h light/dark cycle at the Animal Care Facility of Yamaguchi University Graduate School of Medicine, Ube, Japan. All experiments were performed on 5-to 12-week-old male Wfs1 −/− mice and age-matched male littermate control WT mice. Animal care and experimental procedures were approved by the Animal Ethics Committee of Yamaguchi University Graduate School of Medicine (approval number 25-020) and carried out according to the Yamaguchi University Experimentation Regulations and the NIH guidelines. Randomisation and blinding were carried out for all experiments. The data analysis was performed with all experimental results obtained.
Perfusion experiment Perfusion experiments were performed as previously described [20] . Briefly, we used 10-week-old male mice that had been fasted for 16 h. After induction of anaesthesia, the superior mesenteric and renal arteries were ligated, and the aorta was tied off just below the diaphragm. The perfusate (KRB HEPES [KRBH] buffer supplemented with 4.6% dextran and 0.25% BSA and infused with 95% O 2 /5% CO 2 ) was infused into a catheter placed in the aorta and collected from the portal vein. The perfusion protocol began with the initial step (i.e. from 1 to 5 min; see Figs 1a,c and 2a,c,e) following a 30 min equilibration period using the same buffer. The flow rate of the perfusate was 1 ml/min. For Ex-4 treatment, perfusion with 10 nmol/l Ex-4 (SigmaAldrich, St Louis, MO, USA) was initiated 5 min before perfusion with 16.7 mmol/l glucose and continued for the duration of the observation period. For bafilomycin A1 (BafA1) treatment, the pancreas was perfused with KRBH buffer containing 2.8 mmol/l glucose and 100 nmol/l BafA1 (SigmaAldrich) for 30 min before perfusion with 16.7 mmol/l glucose. The insulin levels in the perfusate were measured using a mouse insulin ELISA kit (Morinaga, Tokyo, Japan).
Total internal reflection fluorescence microscopy analysis Primary cultured beta cells isolated from mouse pancreatic islets of 10-week-old male mice were infected with adenovirus carrying insulin-Venus generated as described previously [21] and were subjected to analysis by total internal reflection fluorescence microscopy (TIRFM) (Olympus, Tokyo, Japan) as previously described [21] . Briefly, cells were preincubated in KRBH containing 4.4 mmol/l glucose for 30 min, and glucose was then added to the chamber to a final concentration of 16.7 mmol/l.
Images were acquired every 250 ms after glucose stimulation. The data analysis was performed using MetaMorph software version 6.1 (Universal Imaging, New York, NY, USA). IPGTT Ten-week-old male Wfs1 −/− and littermate WT mice were subjected to a 6 h fast followed by an intraperitoneal glucose injection (2.0 g/kg). To assess the acute effects of Ex-4, Wfs1 −/− mice were given a single injection of Ex-4 60 min before glucose loading. To assess the chronic effects of Ex-4, mice were given a 48 h drug washout period after the last Ex-4 injection and then underwent an IPGTT after a 12 h fast. Blood glucose levels were measured at 0, 2, 5, 15, 30 and 60 min after injection using an Antsense III (Horiba, Kyoto, Japan), and blood samples were collected from tail vein at the same time intervals. Plasma insulin levels were measured as described above.
Immunohistochemical analysis Mouse pancreas was fixed in 4% paraformaldehyde, embedded in paraffin and sectioned in thicknesses of 4 μm. Serial sections were stained with antibodies (ESM Table 2 ). Immunodetection of phosphorylated AMP-activated kinase (AMPK) required amplification of the primary signal using the TSA kit (Perkin Elmer, Waltham, MA, USA). Images were captured using a Keyence Biozero microscope with the BZ-II software (Keyence, Osaka, Japan). Quantitation of beta cell mass was performed as previously described [22] .
Isolation of islets from mice Islets were isolated from 10-to 12-week-old male mice by ductal collagenase digestion of the pancreas as previously described [10] . All experiments on isolated islets were carried out after 24 h culture following isolation. Isolated islets were incubated with or without 10 nmol/l Ex-4 for 24 h, and gene expression and protein analyses were then carried out.
Protein analysis Proteins extracted from isolated islets were resolved on 4-20% gradient polyacrylamide gels, blotted on to a nitrocellulose membrane. Protein-band densitometry was determined using the same membrane by pixel intensity using NIH Image J software version 1.51s (freely available at http:// rsb.info.nih.gov/ij/index.html) [23] . Antibodies used for immunoblotting are included in ESM Table 3 . The antibodies against WFS1 were generated as described previously [9] . Gene expression analysis We isolated RNA using the PicoPure RNA isolation kit (Thermo Fisher Scientific, Waltham, MA, USA) and DNase I digestion, and synthesised cDNA using the High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, Waltham, MA, USA). We then performed quantitative real-time PCR with PowerUp SYBR Green Master Mix (Applied Biosystems) in an ABI StepOnePlus Real-Time PCR system. We calculated relative gene expression levels by the ΔΔC t method using Cypa (encoding cyclophilin A) as an internal control. Primer sequences are listed in ESM Table 4 .
Statistical analysis Quantitative data are presented as means ± SD. Results were evaluated with a two-tailed Student's t test or one-way ANOVA, as appropriate, with the use of GraphPad Prism software version 7 (GraphPad Software, La Jolla, CA, USA). Significant differences revealed by ANOVA were assessed with Bonferroni's test. A p value <0.05 was considered statistically significant.
Result
Liraglutide modulated beta cell function and improved glycaemic control in an insulin-dependent woman with Wolfram syndrome The woman presented typical diseaserelated clinical features other than neuropsychiatric symptoms (ESM Table 1 ). She carried the WFS1 mutation of the 5-amino-acid in-frame deletion located between a predicted transmembrane domain and a luminal domain of WFS1 (ESM Fig. 1a ). This mutation has deleterious effects on protein expression, accounting for loss of function of WFS1 (ESM Fig. 1b) . The woman weighed 52.6 kg and was not obese. Her daily insulin dose was 40 U, given as a bolus of injection of 18 U, with 22 U as basal insulin, and her glycaemic status was indicated by an HbA 1c of 60 mmol/ mol (7.6%) ( Table 1) . Fasting CPR was very low but detectable (0.077 nmol/l), yielding CPI and SUIT index values of 0.65 nmol/mmol and 2.13, respectively (Table 2 ). In addition, an evaluation of residual insulin reserve yielded ΔCPR and urinary CPR excretion of 0.08 nmol/l and 2.16 nmol/24 h, respectively ( Table 2) .
After initiation of liraglutide treatment, her fasting plasma glucose levels were maintained in the range 7.3-9 mmol/l, and HbA 1c gradually decreased from the baseline of 60 mmol/mol (7.6%) to a minimum of 52 mmol/mol (6.9%) ( Table 1) ; there was also a lower incidence of hypoglycaemia. Although her body weight initially showed a 1.2 kg decrease from baseline, it later returned to baseline values. As her glycaemic control was improving, the daily insulin dose was titrated to achieve a 20% reduction from the baseline dose. Secretory function was assessed by measuring CPR after a 48 h drug washout period. Despite decreased fasting plasma glucose levels, fasting CPR values were maintained above the baseline level (Table 2 .) At 4 weeks after the start of the intervention, the SUIT index and CPI had increased 3.6-and 2.6-fold, respectively, compared with baseline (Table 2) . Increases in the SUIT index and CPI were also evident at 16 weeks. This suggested that clinical use of a GLP-1 receptor agonist might facilitate glycaemic control and even modulate beta cell function in individuals with Wolfram syndrome who are on long-standing insulin therapy.
Glucose and potassium-stimulated insulin secretion are impaired in Wfs1 −/− mice The glucose-lowering effects of the GLP-1 receptor agonist observed in this woman with Wolfram syndrome suggested that its use at an earlier stage of the disease might possibly prevent a deterioration of beta cell function, and thereby modulate progression of diabetes. To better understand the role of WFS1 in regulating beta cell function, we analysed insulin secretion in the perfused pancreases of young Wfs1 −/− mice at 10 weeks of age, in which both fasting and fed blood glucose levels are indistinguishable from those in WT mice. Perfusion with 16.7 mmol/l glucose elicited a marked insulin release in wild-type (WT) mice, whereas the insulin secretion rapidly triggered by glucose was apparently blunted in Wfs1 −/− mice (Fig. 1a) . Insulin secretion in the first phase (6-10 min) was decreased by 53% compared with WT mice (Fig. 1b) . In contrast, insulin secretion in the second phase (11-20 min), was not affected, suggesting that WFS1 is essential for insulin secretion immediately triggered by glucose mediated-depolarisation. In support of this notion, perfusion with 30 mmol/l KCl also failed to stimulate insulin secretion in Wfs1 −/− mice (Fig. 1c) . Insulin secretion during the 10 min period after the initiation of perfusion with KCl was decreased by 59% compared with that in WT mice (Fig.  1d) . To exclude in vivo factors affecting insulin secretion, we assessed insulin secretion from isolated islets. Although basal insulin secretion was not affected in Wfs1 −/− islets, insulin secretion stimulated by glucose and by KCl was significantly decreased, by 36% and 40%, respectively (ESM Fig. 2) . We next investigated the dynamics of insulin granules in living pancreatic beta cells using TIRFM. We classified the modes of insulin granule exocytosis into three classes depending on insulin granule dynamics [21] : (1) (Fig. 1e,f) . The number of fusion events in the first phase (00:00-00:30 to 05:01-05:30 min; where times are presented as min:s) was decreased by 41% compared with that in WT beta cells (Fig. 1g) , whereas the number in the second phase (05:30-06:00 to 15:01-15:30 min) was not affected. Among the three granule classes, only the restless newcomer was found to be involved in the reduced exocytosis (46% reduction; Fig. 1h ).
Activation of GLP-1 receptor stimulates glucose-stimulated insulin secretion in Wfs1
−/− mice We investigated the secretagogue effects of Ex-4 in the perfused pancreas. Ex-4 restored maximum insulin release and persistently potentiated subsequent insulin release (Fig. 2a) . Insulin secretion in the first and second phases was significantly increased, by 3.9-fold and 5.6-fold, respectively, compared with perfusion with saline (154 mmol/l NaCl) as a control; it was 1.6-fold and 3.2-fold higher than that in WT mice, resulting in a significant increase in total insulin secretion (Fig. 2b) . In addition, Ex-4 potentiated glucose-stimulated insulin secretion (GSIS) in isolated islets from Wfs1 −/− mice, which was similar to its effects in WT islets (ESM Fig. 2 ). WFS1 reportedly contributes to the protein stability of vacuolar-type H + -ATPase V1A (ATP6V1a) subunit in human clonal cells [24] . Wfs1 −/− islets exhibited a 44% reduction in expression of this protein compared with WT islets (ESM Fig.  3 ). Because secretory granules are acidified via a proton gradient established and maintained by V-ATPase, inadequate granular acidification in Wfs1 −/− beta cells is probably caused by a failure of V-ATPase function. We therefore examined whether disturbed granular acidification affected GSIS and whether Ex-4 could potentiate GSIS under such conditions. Pretreatment with BafA1, a chemical inhibitor of V-ATPase, severely attenuated GSIS (Fig. 2c ) and resulted in a 67% reduction in insulin secretion (Fig. 2d) . Importantly, Ex-4 apparently potentiated GSIS in the presence of BafA1 (Fig.  2e) . Insulin secretion in the first and second phases increased by 4.8-fold and 22.4-fold, respectively (Fig. 2f) . We next assessed the acute effects of activating GLP-1 receptors in mice under physiological conditions. The 10-weekold Wfs1 −/− mice showed normal baseline blood glucose levels, but an IPGTT revealed that they had glucose intolerance (Fig. 3a) . Ex-4 corrected the glucose excursion in Wfs1 −/− mice, and they then showed better glucose tolerance than WT mice (Fig. 3a,b) . In terms of insulin secretion, Wfs1
−/− mice showed a blunted rapid insulin secretory response (Fig. 3c) . Although the maximal secretory response appeared with a slight delay, Ex-4 potentiated GSIS (Fig. 3c) , resulting in a significantly increased AUC for insulin release during the 15 min period after glucose loading (Fig. 3d) . −/− mice + saline (black squares) and Wfs1 −/− mice + Ex-4 (dark grey triangles). Data are means ± SD (n = 6 for each group). Statistical analyses were performed with ANOVA followed by Bonferroni's post hoc test. *p < 0.05, **p < 0.01, ***p < 0.001 compared with WT mice + saline or Wfs1 −/− mice + saline there was an amelioration of the glucose excursion in Wfs1 −/− mice (Fig. 4b,c) , indicating an off-drug effect of Ex-4. Importantly, the insulin secretory dynamics were indistinguishable from those in WT mice, and, notably, maximal insulin responses appeared at 2 and 15 min, essentially as in WT mice (Fig. 4d) . The AUC for insulin increased by 1.39-fold relative to the control treatment (Fig. 4e) . Treatment with Ex-4 did not alter beta cell mass (Fig. 4f, g ), body weight (ESM Fig.  4a ) or insulin sensitivity (ESM Fig. 4b) . Therefore, improved glucose tolerance with prolonged activation of GLP-1 receptors is likely to be attributable to restored beta cell function.
Beta cell function in

Ex-4 alleviates beta cell stress resulting from Wfs1 deficiency
The restoration of beta cell function suggested that, in addition to its acute amplification of insulin secretion, Ex-4 might also alleviate fundamental defects leading to beta cell dysfunction. To elucidate the effects of Ex-4 on beta cell stress, we assessed phosphorylation on Ser51 of eukaryotic initiation factor 2α (p-EIF2α), which mediates the attenuation of global protein translation in response to various cellular stresses [25] . As shown in Fig. 5a , the overall intensity of immunoreactivity for p-EIF2α appeared to be increased in Wfs1 −/− islet cells compared with WT cells. This was particularly apparent when the relative fluorescence intensities of p-EIF2α were compared between islet cells and acinar cells in the WT and Wfs1 −/− mice (Fig. 5a ). Ex-4 treatment specifically reduced p-EIF2α in islet cells without affecting neighbouring exocrine acinar cells. Concomitantly, the apparently reduced immunoreactivity of insulin in Wfs1 −/− beta cells was partly restored.
We next tested whether Ex-4 was directly modulating stress responses in isolated islets. Oxidative stress-responsive genes including Nrf2 (also known as Nfe2l2), Sod1, Hmox1 and Txnrd1 were significantly elevated in Wfs1 −/− islets (Fig.   5b ). Although increases in Cat (encoding catalase), Sod1 and Txnrd1 were not affected, Ex-4 treatment lowered the overall magnitude of oxidative stress in Wfs1 −/− islets.
Moreover, ER stress-induced transcripts appeared to increase in the Wfs1 −/− islets. Ex-4 significantly lowered Chop (also known as Ddit3) and spliced Xbp1 (sXbp1), but did not affect Bip (also known as Hspa5) and Atf4 (Fig. 5c) . In relation to genes involved in beta cell function, Ex-4 reversed the reductions in Ins2 and Pdx1, and the increase in Ucp2, although the change in Ucp2 was not significant (Fig. 5d) . Collectively, activation of GLP-1 receptors was shown to modulate stress responses against the oxidative and ER stresses imposed by Wfs1 deficiency, and was associated with improved beta cell function.
Ex-4 modulates p-AMPK and thioredoxin interacting protein in Wfs1 −/− beta cells Cell functions under various stressed conditions can be restored by alleviating ER stress, via activation of AMPK [26] [27] [28] . The phosphorylation at Thr172 of AMPK (p-AMPK), which is involved in increasing its own kinase activity, was apparently decreased in Wfs1 −/− beta cells, and was partly restored by Ex-4 (Fig. 5e) . We tested the direct effects of Ex-4 on p-AMPK in isolated islets. Wfs1 −/− islets showed a 30% decrease in p-AMPK/total-AMPK compared with WT islets. Ex-4 significantly increased p-AMPK in both WT and Wfs1 −/− islets, by 46% and 37%, respectively, compared with control, without affecting AMPK expression (Fig.  5g) . Thioredoxin interacting protein (TXNIP), one of the downstream targets of AMPK [29, 30] , is a key mediator of beta cell dysfunction in diabetes and is induced by oxidative and ER stress [31] . Whereas Wfs1 −/− beta cells showed nuclear accumulation of TXNIP, indicating its activation [32] , this was inhibited by Ex-4 ( Fig. 5f ). Production of TXNIP increased by 3.3-fold in Wfs1 −/− islets relative to that in WT islets. Ex-4 significantly reduced TXNIP production in Wfs1 −/− islets, along with increasing p-AMPK (Fig. 5g) .
Activation of AMPK reportedly decreases Txnip transcription in clonal beta cells [29] . Although gene expression of key transcriptional mediators of Txnip, including Atf5 and Chrebp (also known as Mlxipl), was not affected, increased Txnip transcription in Wfs1 −/− islets was reversed by Ex-4 ( Fig. 5h) . These results suggest a correlation between decreased p-AMPK and increased TXNIP in Wfs1 −/− beta cells, and raise the possibility of therapeutic applications of activating GLP-1 receptors through their modulation in association with the alleviation of cellular stress (Fig. 6 ).
Discussion
In Wolfram syndrome, diabetes mellitus progresses together with declining functional beta cell mass, perhaps through processes that initially cause individual cellular dysfunctions. . In addition, we demonstrated that Ex-4 reversed severely impaired GSIS caused by the pharmacological inhibition of V-ATPase, which mimics the disturbed intragranular acidification resulting from WFS1 deficiency [10] . This observation may provide insights into the pathophysiological implications of beta cell dysfunction and the acute actions of GLP-1 receptor agonists in Wfs1 −/− mice. However, the precise function of WFS1 and its roles in secretagogue pathways, including GLP-1 receptor signalling, have yet to be fully elucidated. Future investigations are needed to address these fundamental issues. Chronic administration of Ex-4 restored GSIS in Wfs1
mice via improved functioning of existing beta cells rather than having an effect through increments in beta cell mass. We demonstrated that treatment with Ex-4 decreased stressrelated markers in Wfs1-deficient beta cells and isolated islets, while exerting opposing effects on insulin production. These findings may, at least partly, support previous literature reporting that Ex-4 prevents ER stress-mediated apoptosis by modulating the unfolded protein response in clonal beta cells [35] . However, whereas Wfs1 deficiency increased cellular stress, the rate of beta cell apoptosis did not increase significantly in Wfs1 −/− mice in which normoglycaemia was still maintained (K. Amo-Shiinoki, K. Tanabe, M. Hatanaka and Y. Tanizawa, unpublished data). We therefore speculated that Wfs1 −/− beta cells may adapt to persistent cellular stress through as yet unknown processes, which may be involved in the regulation of cell viability and, perhaps, identity [36] . Anti-stress effects of Ex-4 correlate with reduced TXNIP and partial restoration of p-AMPK, which at least partially elucidates the mechanisms of this reversal [26, 31] . As consistent effects of Ex-4 on TXNIP and p-AMPK were observed in isolated islets, future investigations are needed to elucidate whether these actions of the GLP-1 receptor agonist are direct or a consequence of the mitigation of cellular stress. In our insulin-dependent patient with Wolfram syndrome, liraglutide modulated beta cell function and improved glycaemic control, with a slight reduction in the insulin dose required. These effects persisted, at least for the 6 month observation period, suggesting a possible clinical role of GLP-1-based therapy in Wolfram syndrome. Residual beta cell function was, however, very limited, despite being improved by liraglutide. Moreover, beta cell function peaked at 4 weeks of intervention, and then declined at 16 weeks. This suggests that activation of GLP-1 receptors might only temporarily affect beta cells. Although glucagon levels were not examined in the present study, it is more likely that the effects of liraglutide on gastric emptying rate and alpha cells rather than beta cells may have contributed to the improvement in glycaemic control. On the other hand, whether the endogenous GLP-1 response is affected by WFS1 deficiency has not been investigated. This issue requires further examination to elucidate the significance and efficacy of GLP-1-based therapy in Wolfram syndrome.
The finding that Ex-4 mitigated oxidative and ER stress may have implications for understanding the mechanisms of its action in diabetes mellitus and, more importantly, for treating the neurodegeneration that is a major determinant of the deleterious consequences of this syndrome. In support of this hypothesis, the neuroprotective effects of GLP-1 receptor agonist have been demonstrated in various murine models, and clinical trials have recently been initiated to investigate them in Parkinson's disease and Alzheimer's disease, in which oxidative and ER stress may have pathogenic roles [37] . Based on our finding that Ex-4 mitigated cellular stress while improving function in Wfs1-deficient beta cells, we suggest that GLP-1 receptor agonist therapy may provide a means of attenuating or even slowing the progression of diabetes and neuronal degeneration in individuals with Wolfram syndrome. In addition, a recent study has demonstrated that dantrolene, which targets ryanodine receptors localised to the ER, could be a potential treatment for Wolfram syndrome [18, 38] . Future investigations are needed to elucidate whether a combination of a GLP-1 receptor agonist and dantrolene would have greater therapeutic efficacy.
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